Preparation and physicochemical characterization of atovaquone-containing liposomes

被引:0
作者
Cauchetier, E [1 ]
Fessi, H
Boulard, Y
Deniau, M
Astier, A
Paul, M
机构
[1] CHU Henri Mondor, Serv Pharm, Lab Pharmacotech, F-94010 Creteil, France
[2] Fac Pharm Claude Bernard, Lyon, France
[3] Museum Natl Hist Nat, Lab Biol Parasitaire Protistol & Helminthol, F-75231 Paris, France
[4] Univ H Poincare, Lab Pharm Clin, Nancy, France
关键词
atovaquone; liposomes; physicochemical properties; adsorption;
D O I
10.1002/(SICI)1098-2299(199908)47:4<155::AID-DDR1>3.3.CO;2-W
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This work describes the preparation and the physicochemical properties of atovaquone-loaded liposomes. It also describes drug release from the liposomes. As many factors can influence liposome stability, we studied several formulations, including different concentrations of atovaquone, phospholipids, and cholesterol. The effect of atovaquone (ATV) concentration was also evaluated. The high est binding percentage (100 +/- 2.5%) was obtained under alkaline conditions for a 2 mg/ml concentration of AN. The percentage of encapsulation decreased significantly when drug concentrations increased. Drug uptake (expressed per unit mass of phospholipids) was nonlinearly related to equilibrium ATV concentration. A Langmuir-type sorption was suggested (r = 0.978). in acidic or neutral buffer, the binding percentage reached 42.1 +/- 0.02%. The increase of phospholipids and cholesterol concentrations did not significantly improve the ATV binding yield for the lowest AN concentration. Conversely, ATV binding was significantly increased for the highest ATV concentration. All the formulations tested gave monodispersed liposomes with a mean diameter around 260 nm. The dilution (1/5-1/20) of liposomes in alkaline conditions induced a significant release of ATV (74% release). In acidic or neutral buffer no release was observed, suggesting an encapsulation process. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 41 条
  • [1] ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6
  • [2] THERAPY OF LEISHMANIASIS - SUPERIOR EFFICACIES OF LIPOSOME-ENCAPSULATED DRUGS
    ALVING, CR
    STECK, EA
    CHAPMAN, WL
    WAITS, VB
    HENDRICKS, LD
    SWARTZ, GM
    HANSON, WL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (06) : 2959 - 2963
  • [3] DELIVERY OF LIPOSOME-ENCAPSULATED DRUGS TO MACROPHAGES
    ALVING, CR
    [J]. PHARMACOLOGY & THERAPEUTICS, 1983, 22 (03) : 407 - 424
  • [4] ANTOINE JC, 1995, PATHOL BIOL, V43, P215
  • [5] RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR REVERSES NEUTROPENIA AND REDUCES SECONDARY INFECTIONS IN VISCERAL LEISHMANIASIS
    BADARO, R
    NASCIMENTO, C
    CARVALHO, JS
    BADARO, F
    RUSSO, D
    HO, JL
    REED, SG
    JOHNSON, WD
    JONES, TC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (02) : 413 - 418
  • [6] LIPOSOMES IN THE TREATMENT OF INFECTIONS
    BAKKERWOUDENBERG, IAJM
    STORM, G
    WOODLE, MC
    [J]. JOURNAL OF DRUG TARGETING, 1994, 2 (05) : 363 - 371
  • [7] BARTLETT GR, 1959, J BIOL CHEM, V234, P466
  • [8] Bryceson A., 1987, The leishmaniases in biology and medicine. Volume II. Clinical aspects and control, P847
  • [9] *BURR WELLC, 1992, MEPR PACK INS
  • [10] CABIE A, 1992, PRESSE MED, V21, P1658